Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication currently. Therefore, NICE has decided to suspend this appraisal from its current work programme.
Process STA Standard
ID number 11861

Project Team

Project lead Abbie Stephens

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
11 February 2025 Suspended

For further information on our processes and methods, please see our CHTE processes and methods manual